Effect of omalizumab over a 6-month treatment period on angioedema and quality of life associated with refractory chronic idiopathic/spontaneous urticaria (CIU/CSU): subgroup analyses focused on the presence of baseline angioedema

被引：0

作者：

Maurer, M. ^{[1
]}

Spector, S. ^{[2
]}

Bernstein, J. ^{[3
]}

Gabriel, S. ^{[4
]}

Karagiannis, T. ^{[4
]}

Kianifard, F. ^{[4
]}

Mendelson, M. ^{[4
]}

机构：

[1] Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany

[2] Univ Calif Los Angeles, Med Ctr, Div Clin Allergy & Immunol, Los Angeles, CA 90024 USA

[3] Univ Cincinnati, Coll Med, Dept Internal Med, Allergy Sect,Div Immunol, Cincinnati, OH USA

[4] Novartis Pharmaceut, E Hanover, NJ USA

来源：

ALLERGY | 2015年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

1451

引用

页码：592 / 592

页数：1

共 7 条

[1] Clinical profile of patients with refractory chronic idiopathic/spontaneous urticaria (CIU/CSU) in phase III omalizumab studies: Analyses according to the presence or absence of angioedema
Sofen, Howard
Mendelson, Meryl
Vu, Julie
Kianifard, Farid
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB43 - AB43
[2] Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema
Maurer, M.
Sofen, H.
Ortiz, B.
Kianifard, F.
Gabriel, S.
Bernstein, J. A.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (06) : 1056 - 1063
[3] Omalizumab Improves Quality of Life (QoL) in Patients with Refractory Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Dermatology Life Quality Index (DLQI): A Post-Hoc Analysis of Percent Change from Baseline to Week 12
Rosen, Karin
Khalil, Sam
Balp, Maria-Magdalena
Maurer, Marcus
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB127 - AB127
[4] Omalizumab Improves Quality of Life (QoL) in Patients with Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) As Assessed By the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL): A Post-Hoc Analysis of Percent Change from Baseline to Week 12
Janssens, Nico
Maurer, Marcus
Khalil, Sam
Balp, Maria-Magdalena
Rosen, Karin
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB132 - AB132
[5] Angioedema and angioedema management from ASTERIA II: a phase III, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 antihistamine treatment
Zazzali, J. L.
Rosen, K. E.
Hsieh, H-J
ALLERGY, 2013, 68 : 43 - 43
[6] Omalizumab reduced symptoms and improved health-related quality of life (HRQoL) in patients with refractory chronic spontaneous/idiopathic urticaria (CSU/CIU) in three randomized, double-blind, placebo-controlled phase III trials: a post-hoc analysis of percent change from baseline
Casale, T.
Maurer, M.
Saini, S. S.
Bernstein, J. A.
Kaplan, A.
Rosen, K.
Li, J.
Georgiou, P.
Canvin, J.
ALLERGY, 2014, 69 : 580 - 581
[7] ANGIOEDEMA RESULTS FROM GLACIAL: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETYAND EFFICACY OF OMALIZUMAB IN PATIENTS WITH CHRONIC IDIOPATHIC/SPONTANEOUS URTICARIA (CIU/CSU) RECEIVING CONCOMITANT H1 ANTI-HISTAMINES, H2 ANTIHISTAMINES, AND/OR LEUKOTRIENE RECEPTOR ANTAGONIST (LTRA) TREATMENT
Zazzali, J.
Raimundo, K.
Ashby, M.
Rosen, K.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : A121 - A121

← 1 →